Alnylam Pharmaceuticals, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -2.16%74.170.0%$2384.70m
NVAXNovavax, Inc. -0.98%171.7999.2%$1384.54m
GILDGilead Sciences, Inc. 0.04%69.031.0%$541.19m
SRNESorrento Therapeutics, Inc. -3.81%13.261.8%$507.36m
AMGNAmgen, Inc. -0.56%240.111.3%$489.41m
REGNRegeneron Pharmaceuticals, Inc. 0.06%624.912.5%$460.85m
BNTXBioNTech SE -3.59%78.380.0%$397.79m
VRTXVertex Pharmaceuticals, Inc. -0.68%271.381.9%$378.28m
BIIBBiogen, Inc. 0.15%276.581.6%$328.09m
ILMNIllumina, Inc. -0.18%400.013.5%$320.05m
VXRTVaxart, Inc. -4.64%9.220.0%$309.26m
IBIOiBio, Inc. -1.48%4.330.2%$181.17m
EBSEmergent BioSolutions, Inc. -1.32%132.696.4%$179.84m
SGENSeattle Genetics, Inc. -0.78%161.336.0%$170.77m
ALXNAlexion Pharmaceuticals, Inc. -0.09%102.662.0%$169.60m

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.